Compare i-80 Gold Corp. Common Shares (IAUX) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
i-80 Gold Corp. Common Shares vs Medline Inc. Class A Common Stock — how do they compare? i-80 Gold Corp. Common Shares trades at $1.49 (market cap $1.34B), while Medline Inc. Class A Common Stock trades at $36 (market cap $31.32B). The key difference: Medline Inc. Class A Common Stock is far larger — about 23.4× i-80 Gold Corp. Common Shares's market cap, and i-80 Gold Corp. Common Shares is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Medline Inc. Class A Common Stock for 6 Days on average.
| IAUX | MDLN | |
|---|---|---|
Market Cap | $1.34B | $31.32B |
Volume | 3,239,725 | 4,364,703 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $49.99 |
52-Week Low | $0.89 | $31.64 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.32B | $41.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
